Prestige Consumer Healthcare Inc. (PBH) Stock Price & Analysis
Prestige Consumer Healthcare Inc. (PBH) closed at USD 49.46 on Thursday, October 22, 2026, up 3.21% on the day. The US market is currently closed (pre-market); this is not a live price.
The prior close was USD 49.46; the Oct 22, 2026 session ranged USD 47.5–49.64 on volume of 660,900 shares. Market capitalization is —, with a 52-week range of USD 42.62–71.07 (NYQ). Source: Nexqual, retrieved October 23, 2026 at 09:27 UTC.
Also available as compact Markdown for AI agents: nexqual.com/PBH.md
Key facts (PBH)
- Last four reported quarters (through Jun 30, 2026): revenue $1.10B, net income $172M (15.6% margin), free cash flow $235M (SEC filings).
- 2 of 80 tracked superinvestors hold PBH (13F, Q2 2026): 1 new, 1 added, 0 reduced, 0 unchanged.
- Total return with dividends: 1Y -21.0% vs S&P 500 +14.9%; 5Y -16.5% vs S&P 500 +80.3%.
- Next earnings: 2026-11-05, EPS estimate USD 1.07, revenue estimate $329M.
Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (PBH)
| USD | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $1.09B | $1.13B | $1.13B | $1.14B | $1.09B | $1.10B |
| Gross profit | $621M | $625M | $624M | $634M | $596M | — |
| Operating income | $330M | -$22.4M | $342M | $337M | $309M | $290M |
| Net income | $205M | -$82.3M | $209M | $215M | $190M | $172M |
| EPS (diluted) | $4.04 | -$1.65 | $4.17 | $4.29 | $3.91 | — |
| Free cash flow | $250M | $222M | $239M | $243M | $246M | $235M |
| Gross margin | 57.1% | 55.4% | 55.5% | 55.8% | 54.7% | — |
| Operating margin | 30.4% | -2.0% | 30.4% | 29.6% | 28.4% | 26.3% |
| Net margin | 18.9% | -7.3% | 18.6% | 18.9% | 17.5% | 15.6% |
| Revenue growth | +15.2% | +3.8% | -0.2% | +1.1% | -4.3% | — |
| Cash + short-term investments | $27.2M | $58.5M | $46.5M | $97.9M | $63.9M | — |
| Total debt | $1.48B | $1.35B | $1.14B | $992M | $994M | — |
Fiscal years end Mar. EPS is split-adjusted.
Valuation (price ÷ last four quarters, through Jun 30, 2026) (PBH)
P/E at fiscal year-ends: Mar 2026 15.2x, Mar 2025 20.1x, Mar 2024 17.4x.
Superinvestors (SEC 13F-HR, Q2 2026) (PBH)
2 of 80 tracked investors hold PBH. Each row is the investor's latest 13F; change is vs their prior-quarter share count.
| Investor | Firm | % of portfolio | Value | Change |
|---|---|---|---|---|
| John Rogers | Ariel Investments | 2.29% | $230M | Added +13.9% |
| Lee Ainslie | Maverick Capital | 0.02% | $2.4M | New position |
Total return (dividends reinvested) (PBH)
| 1Y (from 2025-10-23) | 5Y (from 2021-10-18) | |
|---|---|---|
| Total return | -21.0% | -16.5% |
| S&P 500 (SPY) | +14.9% | +80.3% |
| Per year | -21.0% | -3.5% |
| Volatility (annualized) | 33.0% | 25.2% |
| Max drawdown | -36.2% (Feb 2026→Oct 2026) | -49.5% (May 2025→Sep 2026) |
PBH analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends Sep 2026) | $1.07 | $1.10 | -2.9% | $329.1M | 7 |
| Next quarter (ends Dec 2026) | $1.24 | $1.25 | -0.7% | $353.1M | 7 |
| Current fiscal year (ends Mar 2027) | $4.57 | $4.57 | -0.1% | $1.27B | 8 |
| Next fiscal year (ends Mar 2028) | $5.08 | $5.01 | +1.4% | $1.35B | 8 |
Key Statistics (as of October 23, 2026 at 09:27 UTC)
| Price | USD 49.46 |
|---|---|
| Change | ▲ 3.21% (up) |
| Previous Close | USD 49.46 |
| Open | USD 49.46 |
| Day Range | USD 47.5 – 49.64 |
| 52-Week Range | USD 42.62 – 71.07 |
| Volume | 660,900 shares |
| Market Cap | — |
| Exchange | NYQ |
Technical Analysis (PBH)
Nexqual's technical model rates PBH "STRONG BUY" based on 5 bullish and 0 bearish signals across 127 daily candles, as of October 23, 2026 at 09:27 UTC.
| Overall Signal | STRONG BUY |
|---|---|
| RSI (14) | 51.72 (neutral) |
| vs SMA50 | Above (USD 48.86) |
| MACD | 0.32 (positive) |
Earnings (PBH)
| Next Earnings Date | 2026-11-05 |
|---|---|
| EPS Estimate | USD 1.07 |
| Revenue Estimate | $329.13M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD 0.98 vs est 0.88 ▲ beat |
| 2026-03-31 | USD 1.23 vs est 1.39 ▼ miss |
| 2025-12-31 | USD 1.14 vs est 1.16 ▼ miss |
| 2025-09-30 | USD 0.86 vs est 0.97 ▼ miss |
Source: Nexqual, October 23, 2026 at 09:27 UTC.
Financials & Fundamentals (PBH)
| Total Revenue | $1.10B |
|---|---|
| Revenue Growth (latest quarter, YoY) | +6.50% |
| Gross Margin | +54.77% |
| Operating Margin | +20.83% |
| Profit Margin | +15.57% |
| ROE | +9.12% |
| Debt / Equity | 1.08 |
| Current Ratio | 3.23 |
| Total Cash | $89.13M |
| Total Debt | $2.07B |
Source: Nexqual, October 23, 2026 at 09:27 UTC.
Ownership (PBH)
| Insider Ownership | +1.41% |
|---|---|
| Institutional Ownership | +116.55% |
| Shares Outstanding | 47.37M |
| Float | 46.70M |
| Short % of Float | +11.83% |
Source: Nexqual, October 23, 2026 at 09:27 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| BHC | Bausch Health Companies Inc. | USD 6.49 | ▲ 0.62% |
| SUPN | Supernus Pharmaceuticals, Inc. | USD 42.07 | ▲ 2.09% |
| HCM | HUTCHMED (China) Limited | USD 14.28 | ▼ 0.63% |
| LQDA | Liquidia Corporation | USD 39.69 | ▲ 2.14% |
| AMLX | Amylyx Pharmaceuticals, Inc. | USD 28.57 | ▼ 1.58% |
| INDV | Indivior Pharmaceuticals, Inc. | USD 35.33 | ▲ 1.55% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 23, 2026 at 09:27 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt